ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland

ABIVAX presented this week new pre-clinical data on ABX464 during scientific conference on “HIV Drug Therapy” in Glasgow, Scotland

Results indicate that reservoir cells may be key target for ABX464’s primary metabolite

Paris, October 27th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new pre-clinical data on ABX464, ABIVAX’s first-in-class drug candidate for the treatment of patients with HIV/AIDS, during this week’s HIV Drug Therapy 2016 meeting in Glasgow, Scotland. ABIVAX’s presentation is entitled, “Differential effects of ABX464 and its primary metabolite ABX464-NGlc on HIV replication in human PBMC’s and macrophages: implications for treatment strategies to eliminate the reservoirs”. 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41